Kura Oncology, Inc. - 8-K Filing
Kura Oncology's stockholders approved amendments increasing share reserves under its equity incentive plan by 6.5 million shares and employee stock purchase plan by 2.5 million shares on June 4, 2026. The vote also elected three Class III directors (Diane Parks, Mary T. Szela, Michael J. Vasconcelles), ratified Ernst & Young as auditors, approved executive compensation ('Say-on-Pay'), and set annual frequency for future Say-on-Pay votes. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $KURA